Trending...
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
PITTSBURGH, July 25, 2024 ~ PANTHERx Rare, one of the leading rare disease specialty pharmacies in the nation, has announced the appointment of Bansi Nagji as their new CEO effective August 1, 2024. Mr. Nagji, who has been serving as a member of the company's board of directors, will now take on the additional responsibility of leading PANTHERx Rare as its CEO. This change in leadership comes as Rob Snyder, the current co-founder and CEO, transitions to a full-time role as Executive Chair.
With over 25 years of experience in various leadership roles within the healthcare industry, Mr. Nagji brings a wealth of knowledge and expertise to his new position. He has a strong background in pharma services and supply chain management, healthcare technology, and digital platforms. Throughout his career, he has successfully led high-growth businesses and implemented effective strategies for organic and inorganic growth. Prior to joining PANTHERx Rare as Executive Chair in December 2023, Mr. Nagji served as President of Healthcare at GoodRx Inc., as well as Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation. He also has extensive experience serving on the boards of private and public companies such as Change Healthcare, Deloitte, and Parata Systems.
More on The PennZone
Meanwhile, Dr. Snyder's transition to full-time Executive Chair marks a significant milestone for PANTHERx Rare since its founding in 2011. As CEO, he played a crucial role in driving the organization's growth and transformation through various clinical, operational, and business development initiatives that have continued to benefit patients. In his new role as Executive Chair, Dr. Snyder will focus on collaborating with industry partners to ensure that PANTHERx Rare maintains its reputation for providing quality patient access to essential medications.
Expressing his excitement about taking on the role of CEO at PANTHERx Rare, Mr. Nagji said that he was looking forward to leading the company through its next phase of growth. He acknowledged Dr. Snyder's leadership and the significant impact he has had on the organization since its inception. Mr. Nagji also shared his passion for building businesses that help people gain access to critical medications and expressed his eagerness to use his experience to support PANTHERx Rare's mission of helping those living with rare diseases. He also praised the company's patient-centric culture and expressed his desire to continue working closely with Dr. Snyder in his new role as Executive Chair.
More on The PennZone
Dr. Snyder, on the other hand, reflected on PANTHERx Rare's journey so far and their goal of improving every aspect of the patient experience. He expressed his excitement about dedicating his full-time focus to developing innovative access and support services for patients along their health journey. Dr. Snyder also expressed confidence in Mr. Nagji's abilities and was eager to continue working with him as PANTHERx Rare enters its next phase of growth.
These executive appointments are a testament to PANTHERx Rare's commitment to providing expert and empathetic patient care, as well as their strong leadership bench and rapidly growing team of professionals. With Mr. Nagji at the helm, supported by Dr. Snyder in his new role, PANTHERx Rare is poised for continued success in delivering quality care for those living with rare diseases.
With over 25 years of experience in various leadership roles within the healthcare industry, Mr. Nagji brings a wealth of knowledge and expertise to his new position. He has a strong background in pharma services and supply chain management, healthcare technology, and digital platforms. Throughout his career, he has successfully led high-growth businesses and implemented effective strategies for organic and inorganic growth. Prior to joining PANTHERx Rare as Executive Chair in December 2023, Mr. Nagji served as President of Healthcare at GoodRx Inc., as well as Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation. He also has extensive experience serving on the boards of private and public companies such as Change Healthcare, Deloitte, and Parata Systems.
More on The PennZone
- Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
- Can Government Operate Better Through Innovation?
Meanwhile, Dr. Snyder's transition to full-time Executive Chair marks a significant milestone for PANTHERx Rare since its founding in 2011. As CEO, he played a crucial role in driving the organization's growth and transformation through various clinical, operational, and business development initiatives that have continued to benefit patients. In his new role as Executive Chair, Dr. Snyder will focus on collaborating with industry partners to ensure that PANTHERx Rare maintains its reputation for providing quality patient access to essential medications.
Expressing his excitement about taking on the role of CEO at PANTHERx Rare, Mr. Nagji said that he was looking forward to leading the company through its next phase of growth. He acknowledged Dr. Snyder's leadership and the significant impact he has had on the organization since its inception. Mr. Nagji also shared his passion for building businesses that help people gain access to critical medications and expressed his eagerness to use his experience to support PANTHERx Rare's mission of helping those living with rare diseases. He also praised the company's patient-centric culture and expressed his desire to continue working closely with Dr. Snyder in his new role as Executive Chair.
More on The PennZone
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
- Her Song Lives On: Remembering Mrs. Darlene Davis Porter
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
Dr. Snyder, on the other hand, reflected on PANTHERx Rare's journey so far and their goal of improving every aspect of the patient experience. He expressed his excitement about dedicating his full-time focus to developing innovative access and support services for patients along their health journey. Dr. Snyder also expressed confidence in Mr. Nagji's abilities and was eager to continue working with him as PANTHERx Rare enters its next phase of growth.
These executive appointments are a testament to PANTHERx Rare's commitment to providing expert and empathetic patient care, as well as their strong leadership bench and rapidly growing team of professionals. With Mr. Nagji at the helm, supported by Dr. Snyder in his new role, PANTHERx Rare is poised for continued success in delivering quality care for those living with rare diseases.
0 Comments
Latest on The PennZone
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- SMACK Fight Week Takes Over Philadelphia
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Brewtay Coffee Introduces Specialty Instant Line Designed for High-Velocity Commuters and Travelers
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
- IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)